Oncology On The Go

CancerNetwork spoke with Kami Maddocks MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University, about CD-19 directed agents, avoiding rechallenging with rituximab, and second-line outcomes for transplant-ineligible patients with diffuse large B-cell lymphoma (DLBCL). 
Visit cancernetwork.com to check out the first episode of this 3-part series here.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork® examined an article from the June issue of the journal ONCOLOGY® titled “Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer” by speaking with one of the authors, Robert A. Figlin, MD. Figlin, who is a professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology-Oncology, and deputy director of Cedars-Sinai Cancer at the Cedars-Sinai Medical Center in Los Angeles, California, spoke about the evolving treatment paradigm of metastatic clear cell renal cell carcinoma, specifically how the shifting landscape of first-line therapies has impacted second-line therapeutic strategies. He discussed standard therapeutic strategies in this space, such as the use of immunotherapy and tyrosine kinase inhibitors, and how new data affect where these agents fit in to patient care. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Benjamin Levy, MD, of the John Hopkins Sidney Kimmel Comprehensive Cancer Center, to discuss frontline management of extensive-stage small cell lung cancer (SCLC) and the recent updates in the field. In the video series, Levy discussed the following: ·      Small Cell Lung Cancer: Risk and Prognosis

·      Small Cell Lung Cancer: Standard of Care

·      Extensive-Stage Small Cell Lung Cancer: Gaps in Treatment

·      Immunotherapy for First-Line Extensive-Stage SCLC

·      First-Line I-O Plus Chemotherapy for Extensive-Stage SCLC

·      Significance of the IMpower133 Trial in Extensive-Stage SCLC

 To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.

In this episode, CancerNetwork spoke with 2 experts on the topic of biosimilars, Howard Hochster, MD, FACP, Associate Director for Clinical Research at the Rutgers Cancer Institute of New Jersey and Distinguished Professor of Medicine at the Rutgers School of Medicine, and Michael Kane, RPh, BCOP, Executive Director of Oncology Pharmacy Services for RWJBarnabas Health and Director of Pharmacy Services and the Research Pharmacy at the Rutgers Cancer Institute of New Jersey.
The episode dives into the background of biosimilars, including the Biologics Price Competition and Innovation Act (BPCIA) passed by the United States Congress in 2009 and subsequent 4-letter suffix rule used to identify biologics products without confusion. The conversation also analyzed some of the unintended consequences of these actions regarding biosimilars, and what Hochster and Kane would do to improve the system that’s currently in place.

In this episode, CancerNetwork spoke with Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, about recently approved and emerging treatment regimens for transplant-ineligible diffuse large B-cell lymphoma (DLBCL).

Salles discussed some of the available treatment options including tafasitamab, CAR T-cell therapies, selinexor, and antibody drug conjugates (ADCs). He also looked ahead at some of the upcoming research on the horizon, including the B-MIND trial investigating tafasitamab or rituximab plus bendamustine.

As part of the OncView video series, CancerNetwork spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida about updates in the management of extensive-stage small cell lung cancer (ES-SCLC). Socinski touched on a number of important aspects of treating this disease, including the existing standards of care, treatment challenges, immunotherapy, IMpower 133 trial, and more.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.

This week, "Oncology Peer Review On-The-Go" discussed an article from the May issue of the journal ONCOLOGY titled “Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians.” CancerNetwork spoke with Christine Chung, DO, from the HCA Swedish Medical Center in Englewood, Colorado, about the molecular profiling patterns she and her colleagues observed in this retrospective review. The authors found that both academic and community physicians ordered profiling about 50% of the time, which was contrary to previous reports that suggest academic centers perform molecular profiling more often.

The perspective for this article comes from Roman Groisberg, MD, a medical oncologist and director of the Sarcoma Medical Oncology Program at the Rutgers Cancer Institute. Groisberg discussed the role of profiling in pancreatic adenocarcinoma, his thoughts on the retrospective review, and the future of profiling for this cohort of patients.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Sameh Gaballa, MD, of the Moffit Cancer Center, about current and future treatment options, and considerations for patients with relapsed/refractory follicular lymphoma. In the video series, Gaballa discussed the following:·      Treatment Options in Relapsed/Refractory Follicular Lymphoma

·      Considerations for Treatment Selection in R/R FL

·      Third-Line Therapy in Follicular Lymphoma

·      Tazemetostat for Relapsed/Refractory Follicular Lymphoma

·      R/R FL: The Role of PI3K Inhibitors

·      Unmet Needs and Looking Ahead in Follicular Lymphoma

 To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

The May issue of the journal ONCOLOGY featured a review article titled “Primary Focal Therapy for Localized Prostate Cancer: A Review of the Literature.” Sudhir Isharwal, MD, an assistant professor in the Department of Urology at Oregon Health & Science University in Portland, Oregon, discussed the emergence of focal therapies in the last few years for the treatment of patients with localized prostate cancer. This literature review investigated some of the advantages and drawbacks of various therapeutic models in this space.

The perspective for this article was written by Thomas Polascik, MD, a professor of Surgery/Urology and director of Focal Therapy at the Duke Cancer Center, Duke Medical Center in Durham, North Carolina. Polascik discussed the response he wrote to this article, titled “Prostate Cancer Focal Therapy Has Made Great Strides and the Future Remains Bright.” He touched on all aspects of focal therapy, including history, potential hurdles, and patient selection and surveillance, among other things. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

The feature article for this episode comes from the April issue of the Journal ONCOLOGY titled “Treatment Considerations for Transplant-Ineligible Multiple Myeloma.” Sarah Holstein, MD, an associate professor of internal medicine in the Division of Oncology & Hematology at University of Nebraska Medical Center in Omaha, Nebraska, spoke about the need for further research into treatment options for the older and more frail patient population of multiple myeloma.

Holstein also explained the importance of understanding results from multiple myeloma clinical trials through the lens of how they apply to this specific transplant-ineligible population. 

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.